Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation of why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma... via Health News from Medical News Today Read More Here..
No comments:
Post a Comment